MRI confirms effectiveness of beta-thalassemia treatment
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for beta-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
British researchers have used T2* measures of cardiac iron loading to show the value of a new drug treatment for beta-thalassemia, a genetic blood disorder. The laborious clinical trial involved transporting a mobile MRI system three times from London to the Mediterranean island of Sardinia.
Researchers found a 40% increase in T2* values, which represents a statistically significant drop in myocardial iron among beta-thalassemia patients who received a combined deferoxamine/deferiprone treatment for 12 months, according to Dr. Mark A. Tanner, a contrast MR researcher at Royal Brompton Hospital in London. T2* increases in the placebo-treated group were much smaller.
The results suggest that combined deferoxamine/deferiprone therapy will reduce the likelihood of cardiac iron loading and the threat of lethal complications, Tanner said.
"I suggest that combined therapy be considered in all patients who fail to achieve adequate iron load status on deferoxamine alone," he said.
This special section was compiled by James Brice, senior editor of Diagnostic Imaging.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
